Skip to main content
Figure 1 | BMC Cancer

Figure 1

From: Rac3 induces a molecular pathway triggering breast cancer cell aggressiveness: differences in MDA-MB-231 and MCF-7 breast cancer cell lines

Figure 1

Efficacy and specificity of siRNA anti-Rac3 treatment and effect on RhoA activation in cancer cells and normal mammary epithelial cells. Cells were incubated with 10 nM siRNA (control or anti-Rac3) for 48 h or 72 h, proteins or mRNA were then extracted. (A) RT-PCR was performed to verify the efficiency of Rac3 siRNA. (B) Western blot. (C) Western blot performed to verify the specificity of the Rac3 siRNA. (D) RhoA activation monitored by G-Lisa. Mean ± S.E., N=3 independent experiments. * P<0.05; ***P<0.001.

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us